Atom Investors’s Immunome IMNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$13.1M Buy
608,277
+310,788
+104% +$7.71M 0.73% 10
2026
Q2
$6.3M Sell
297,489
-9,391
-3% -$201K 0.56% 14
2026
Q1
$6.71M Buy
306,880
+131,113
+75% +$2.92M 0.48% 38
2025
Q4
$3.78M Buy
+175,767
New +$3.08M 0.3% 115
2022
Q2
– Sell
-39,770
Closed -$226K – 287
2022
Q1
$226K Sell
39,770
-6,088
-13% -$45.5K 0.11% 161
2021
Q4
$594K Buy
+45,858
New +$818K 0.1% 148

Other funds holding IMNM

Atom Investors's IMNM Position: Q3 2026 in Review

Atom Investors increased its Immunome (IMNM) stake by 104% in Q3 2026, buying an estimated $7.71M and bringing the position to 608,277 shares worth $13.1M. The position accounts for 0.73% of the portfolio, ranked #10.

Atom Investors first reported a position in IMNM in Q4 2021 and has held it in 6 quarters since. 211 funds tracked by Wall St. Rank hold IMNM as of Q3 2026.

  • Atom Investors held 608,277 shares of Immunome worth $13.1M as of Q3 2026.
  • Atom Investors bought 310,788 Immunome shares in Q3 2026, an estimated $7.71M.
  • Immunome made up 0.73% of Atom Investors's portfolio in Q3 2026, its #10 holding.
  • Atom Investors first reported a position in Immunome in Q4 2021 and has held it in 6 quarters since.
  • 211 funds tracked by Wall St. Rank held Immunome as of Q3 2026.

Based on Atom Investors's 13F filing for Q3 2026, filed 16 Nov 2026.